Chenguang W.
About Chenguang W.
Chenguang W. is a Senior Scientist at Evelo Biosciences in Cambridge, Massachusetts, with expertise in developing oral solid dosage forms and drug delivery systems. He has a Ph.D. in Pharmaceutical Sciences and has previously worked at the University of Minnesota-Twin Cities in various research roles.
Work at Evelo Biosciences
Chenguang W. has been employed as a Senior Scientist at Evelo Biosciences since 2021. In this role, he focuses on the development of immediate-release oral solid dosage forms. His work includes the formulation of orally disintegrating and chewable tablets. Based in Cambridge, Massachusetts, he contributes to the company's research and development efforts, leveraging his expertise in pharmaceutical sciences.
Experience at University of Minnesota-Twin Cities
Prior to joining Evelo Biosciences, Chenguang W. worked at the University of Minnesota-Twin Cities. He served as a Researcher 5 from 2019 to 2021, where he engaged in advanced research projects. Before that, he was a Post/Doctoral Associate in the Pharmaceutical Materials Science and Engineering Laboratory from 2016 to 2019. His time at the university spanned a total of five years, during which he developed a strong foundation in pharmaceutical sciences.
Education and Expertise
Chenguang W. earned his Doctor of Philosophy (Ph.D.) in Pharmaceutical Sciences from Huazhong University of Science and Technology, completing his studies from 2011 to 2016. His academic background provides him with a solid understanding of drug formulation and delivery systems. He specializes in the viscoelasticity of pharmaceutical materials and utilizes computational tools such as FHI-aims, Material Studio, and CrystalExplorer to analyze organic crystal structures.
Research and Development Contributions
Chenguang W. has made significant contributions to the field of pharmaceutical sciences through his research on drug delivery systems. He employs ionic liquids to develop novel drug delivery systems, particularly focusing on small molecular drug combinations. Additionally, he has developed a streamlined high-dose tablet using roller compaction, demonstrating his ability to innovate in tablet formulation processes.